Strik A - Search Results

1

Personalized Dosing of Infliximab in Patients With Inflammatory Bowel Disease Using a Bayesian Approach: A Next Step in Therapeutic Drug Monitoring.

Desai DC, Dherai AJ, Strik A, Mould DR. Desai DC, et al. Among authors: strik a. J Clin Pharmacol. 2023 Apr;63(4):480-489. doi: 10.1002/jcph.2189. Epub 2022 Dec 29. J Clin Pharmacol. 2023. PMID: 36458468 Review.

2

Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial.

Strik AS, Löwenberg M, Mould DR, Berends SE, Ponsioen CI, van den Brande JMH, Jansen JM, Hoekman DR, Brandse JF, Duijvestein M, Gecse KB, de Vries A, Mathôt RA, D'Haens GR. Strik AS, et al. Scand J Gastroenterol. 2021 Feb;56(2):145-154. doi: 10.1080/00365521.2020.1856405. Epub 2020 Dec 8. Scand J Gastroenterol. 2021. PMID: 33290108 Clinical Trial.

3

Therapeutic drug monitoring-based dosing of TNF inhibitors in inflammatory bowel disease: the way forward?

Strik AS, Berends SE, Löwenberg M. Strik AS, et al. Expert Rev Clin Pharmacol. 2019 Sep;12(9):885-891. doi: 10.1080/17512433.2019.1642745. Epub 2019 Jul 18. Expert Rev Clin Pharmacol. 2019. PMID: 31305158 Review.

4

Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease.

Strik AS, Bots SJ, D'Haens G, Löwenberg M. Strik AS, et al. Expert Rev Clin Pharmacol. 2016;9(3):429-39. doi: 10.1586/17512433.2016.1133288. Epub 2016 Jan 28. Expert Rev Clin Pharmacol. 2016. PMID: 26681400 Review.

5

Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease.

Strik AS, van den Brink GR, Ponsioen C, Mathot R, Löwenberg M, D'Haens GR. Strik AS, et al. Aliment Pharmacol Ther. 2017 Apr;45(8):1128-1134. doi: 10.1111/apt.13994. Epub 2017 Feb 23. Aliment Pharmacol Ther. 2017. PMID: 28230306

6

Hemolytic anemia after switching from infliximab originator to biosimilar CT-P13 in a patient with inflammatory bowel disease: A case report.

Strik AS, D'Haens GR, Löwenberg M. Strik AS, et al. Clin Case Rep. 2019 Sep 21;7(11):2049-2053. doi: 10.1002/ccr3.2394. eCollection 2019 Nov. Clin Case Rep. 2019. PMID: 31788249 Free PMC article.

7

Monitoring of Adalimumab Concentrations at Home in Patients with Inflammatory Bowel Disease Using Dried Blood Samples.

Berends SE, Bloem K, de Vries A, Schaap T, Rispens T, Strik AS, Talwar R, Löwenberg M, D'Haens GR, Mathôt RA. Berends SE, et al. Among authors: strik as. Ther Drug Monit. 2020 Apr;42(2):289-294. doi: 10.1097/FTD.0000000000000686. Ther Drug Monit. 2020. PMID: 31464823

8

Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis.

Berends SE, Strik AS, Löwenberg M, D'Haens GR, Mathôt RAA. Berends SE, et al. Among authors: strik as. Clin Pharmacokinet. 2019 Jan;58(1):15-37. doi: 10.1007/s40262-018-0676-z. Clin Pharmacokinet. 2019. PMID: 29752633 Free PMC article. Review.

9

Explaining Interpatient Variability in Adalimumab Pharmacokinetics in Patients With Crohn's Disease.

Berends SE, Strik AS, Van Selm JC, Löwenberg M, Ponsioen CY, DʼHaens GR, Mathôt RA. Berends SE, et al. Among authors: strik as. Ther Drug Monit. 2018 Apr;40(2):202-211. doi: 10.1097/FTD.0000000000000494. Ther Drug Monit. 2018. PMID: 29529008

10

Letter: the addition of an immunosuppressant in patients with unsatisfactory response to vedolizumab-Authors' reply.

Strik AS, D'Haens GR. Strik AS, et al. Aliment Pharmacol Ther. 2018 Apr;47(7):1041-1042. doi: 10.1111/apt.14570. Aliment Pharmacol Ther. 2018. PMID: 29512914 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

31 results

Search Page

Filters